Number of the records: 1  

DNA interactions of antitumor doxorubicin and its more potent analog 2 pyrrolinodoxorubicin

  1. 1.
    SYSNO ASEP0328521
    Document TypeA - Abstract
    R&D Document TypeThe record was not marked in the RIV
    R&D Document TypeNení vybrán druh dokumentu
    TitleDNA interactions of antitumor doxorubicin and its more potent analog 2 pyrrolinodoxorubicin
    Titlestudium interakce protinádorového léčiva doxorubicinu a jeho analogu 2-pyrrolinodoxorubicinem s DNA
    Author(s) Štěpánková, Jana (BFU-R)
    Vrána, Oldřich (BFU-R) RID
    Studenovský, Martin (UMCH-V) RID, ORCID
    Brabec, Viktor (BFU-R) RID, ORCID
    Source TitleAbstract. - Genoa, 2009 - ISSN 0175-7571
    S66
    Number of pages1 s.
    Action7th EBSA, European Biophysics Congress Genoa
    Event date11.07.2009-15.07.2009
    VEvent locationGenoa
    CountryIT - Italy
    Event typeEUR
    Languageeng - English
    CountryIT - Italy
    Keywordsdoxorubicin ; 2-pyrrolinodoxorubicin ; DNA
    Subject RIVBO - Biophysics
    R&D ProjectsGD301/09/H004 GA ČR - Czech Science Foundation (CSF)
    CEZAV0Z50040507 - BFU-R (2005-2011)
    AV0Z50040702 - BFU-R (2007-2013)
    AV0Z40500505 - UMCH-V (2005-2011)
    AnnotationThe results of the mechanistic study confirm that p-DOX is an efficient DNA intercalator and that it can readily form covalent DNA adducts (interstrand crosslinks) independently of pH and in absence of formaldehyde. We suggest that these features of DNA binding mode of p-DOX are responsible for a dramatic enhancement of its toxicity in tumor cell lines in comparison with conventional DOX observed earlier.
    WorkplaceInstitute of Biophysics
    ContactJana Poláková, polakova@ibp.cz, Tel.: 541 517 244
    Year of Publishing2010
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.